These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 33650100)

  • 41. Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.
    Jakubowiak AJ; Jasielec JK; Rosenbaum CA; Cole CE; Chari A; Mikhael J; Nam J; McIver A; Severson E; Stephens LA; Tinari K; Rosebeck S; Zimmerman TM; Hycner T; Turowski A; Karrison T; Zonder JA
    Br J Haematol; 2019 Aug; 186(4):549-560. PubMed ID: 31124580
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial.
    Dytfeld D; Wróbel T; Jamroziak K; Kubicki T; Robak P; Walter-Croneck A; Czyż J; Tyczyńska A; Druzd-Sitek A; Giannopoulos K; Nowicki A; Szczepaniak T; Łojko-Dankowska A; Matuszak M; Gil L; Puła B; Rybka J; Majcherek M; Usnarska-Zubkiewicz L; Szukalski Ł; Końska A; Zaucha JM; Walewski J; Mikulski D; Czabak O; Robak T; Lahoud OB; Zonder JA; Griffith K; Stefka A; Major A; Derman BA; Jakubowiak AJ
    Lancet Oncol; 2023 Feb; 24(2):139-150. PubMed ID: 36642080
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.
    Shah JJ; Stadtmauer EA; Abonour R; Cohen AD; Bensinger WI; Gasparetto C; Kaufman JL; Lentzsch S; Vogl DT; Gomes CL; Pascucci N; Smith DD; Orlowski RZ; Durie BG
    Blood; 2015 Nov; 126(20):2284-90. PubMed ID: 26384354
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study.
    Bringhen S; Petrucci MT; Larocca A; Conticello C; Rossi D; Magarotto V; Musto P; Boccadifuoco L; Offidani M; Omedé P; Gentilini F; Ciccone G; Benevolo G; Genuardi M; Montefusco V; Oliva S; Caravita T; Tacchetti P; Boccadoro M; Sonneveld P; Palumbo A
    Blood; 2014 Jul; 124(1):63-9. PubMed ID: 24855212
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
    Stewart AK; Rajkumar SV; Dimopoulos MA; Masszi T; Špička I; Oriol A; Hájek R; Rosiñol L; Siegel DS; Mihaylov GG; Goranova-Marinova V; Rajnics P; Suvorov A; Niesvizky R; Jakubowiak AJ; San-Miguel JF; Ludwig H; Wang M; Maisnar V; Minarik J; Bensinger WI; Mateos MV; Ben-Yehuda D; Kukreti V; Zojwalla N; Tonda ME; Yang X; Xing B; Moreau P; Palumbo A;
    N Engl J Med; 2015 Jan; 372(2):142-52. PubMed ID: 25482145
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Microangiopathy in multiple myeloma: a case of carfilzomib-induced secondary thrombotic microangiopathy successfully treated with plasma exchange and complement inhibition.
    Catanese L; Link K; Rupprecht H
    BMC Nephrol; 2023 Jun; 24(1):179. PubMed ID: 37337151
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study.
    Biran N; Siegel D; Berdeja JG; Raje N; Cornell RF; Alsina M; Kovacsovics T; Fang B; Kimball AS; Landgren O
    Am J Hematol; 2019 Jul; 94(7):794-802. PubMed ID: 31021005
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS).
    Hájek R; Masszi T; Petrucci MT; Palumbo A; Rosiñol L; Nagler A; Yong KL; Oriol A; Minarik J; Pour L; Dimopoulos MA; Maisnar V; Rossi D; Kasparu H; Van Droogenbroeck J; Yehuda DB; Hardan I; Jenner M; Calbecka M; Dávid M; de la Rubia J; Drach J; Gasztonyi Z; Górnik S; Leleu X; Munder M; Offidani M; Zojer N; Rajangam K; Chang YL; San-Miguel JF; Ludwig H
    Leukemia; 2017 Jan; 31(1):107-114. PubMed ID: 27416912
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience of Rete Ematologica Pugliese (REP).
    Mele A; Prete E; De Risi C; Citiso S; Greco G; Falcone AP; Sanpaolo G; Mele G; Giannotta A; Vergine C; Reddiconto G; Palazzo G; Sabatelli S; Germano C; Miccolis R; Curci P; Palumbo G; Offidani M; Rizzi R; Cascavilla N; Pastore D; Di Renzo N; Mazza P; Tarantini G; Guarini A; Capalbo S; Specchia G; Greco A; De Francesco R; Sibilla S; Tonialini L; Morciano MR; Pavone V
    Ann Hematol; 2021 Feb; 100(2):429-436. PubMed ID: 33161453
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Reversible renal-limited thrombotic microangiopathy due to gemcitabine-dexamethasone-cisplatin therapy: a case report.
    Nishikubo M; Shimomura Y; Hiramoto N; Sawamura N; Yamaguchi T; Hara S; Ishikawa T
    BMC Nephrol; 2021 May; 22(1):175. PubMed ID: 33980166
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Carfilzomib, thalidomide, and dexamethasone are safe and effective in relapsed and/or refractory multiple myeloma: final report of the single-arm, multicenter, phase II ALLG MM018/AMN002 study.
    Ninkovic S; Harrison SJ; Lee JJ; Murphy N; Lee JH; Estell J; Chen VM; Horvath N; Kim K; Eek R; Augustson B; Bang SM; Huang SY; Rajagopal R; Szabo F; Engeler D; Butcher BE; Mollee P; Durie B; Chng WJ; Quach H
    Haematologica; 2024 Jul; 109(7):2229-2238. PubMed ID: 38235519
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Complement as the enabler of carfilzomib-induced thrombotic microangiopathy.
    Blasco M; Martínez-Roca A; Rodríguez-Lobato LG; Garcia-Herrera A; Rosiñol L; Castro P; Fernández S; Quintana LF; Cibeira MT; Bladé J; Fernández de Larrea C; Tovar N; Jimenez R; Poch E; Guillen E; Campistol JM; Carreras E; Diaz-Ricart M; Palomo M
    Br J Haematol; 2021 Apr; 193(1):181-187. PubMed ID: 32469083
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial.
    Wester R; van der Holt B; Asselbergs E; Zweegman S; Kersten MJ; Vellenga E; van Marwijk Kooy M; de Weerdt O; Minnema M; Lonergan S; Palumbo A; Lokhorst H; Broijl A; Sonneveld P
    Haematologica; 2019 Nov; 104(11):2265-2273. PubMed ID: 30948492
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Randomized phase II study of weekly carfilzomib 70 mg/m
    Puertas B; González-Calle V; Sureda A; Moreno MJ; Oriol A; González E; Rosiñol L; López J; Escalante F; Martínez-Lopez J; Carrillo E; Clavero E; Ríos-Tamayo R; Rey-Bua B; González-Rodríguez AP; Dourdil V; De Arriba F; González S; Pérez-de-Oteyza J; Hernández MT; García-Mateo A; Bargay J; Bladé J; Lahuerta JJ; San Miguel JF; Ocio EM; Mateos MV
    Haematologica; 2023 Oct; 108(10):2753-2763. PubMed ID: 37102598
    [TBL] [Abstract][Full Text] [Related]  

  • 55. An observational study of once-weekly carfilzomib in patients with multiple myeloma in Japan (Weekly-CAR study).
    Abe Y; Kubonishi S; Ri M; Iino M; Sunami K; Ito T; Fukaya M; Kitano T; Ikeda S; Ota S; Kuroi T; Iriyama N; Jo T; Adachi M; Akahane D; Kai T; Kohara Y; Kadowaki N; Katayama T
    Future Oncol; 2024; 20(17):1191-1205. PubMed ID: 38420911
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathy.
    Moscvin M; Liacos CI; Chen T; Theodorakakou F; Fotiou D; Hossain S; Rowell S; Leblebjian H; Regan E; Czarnecki P; Bagnoli F; Bolli N; Richardson P; Rennke HG; Dimopoulos MA; Kastritis E; Bianchi G
    Blood Cancer J; 2023 Feb; 13(1):31. PubMed ID: 36849497
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.
    Jackson GH; Davies FE; Pawlyn C; Cairns DA; Striha A; Collett C; Waterhouse A; Jones JR; Kishore B; Garg M; Williams CD; Karunanithi K; Lindsay J; Wilson JN; Jenner MW; Cook G; Kaiser MF; Drayson MT; Owen RG; Russell NH; Gregory WM; Morgan GJ;
    Lancet Haematol; 2019 Dec; 6(12):e616-e629. PubMed ID: 31624047
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The role of carfilzomib in treatment of newly diagnosed multiple myeloma.
    Strifler S; Knop S
    Future Oncol; 2018 Dec; 14(30):3123-3134. PubMed ID: 30058374
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Isatuximab plus carfilzomib-dexamethasone versus carfilzomib-dexamethasone in patients with relapsed multiple myeloma (IKEMA): overall survival analysis of a phase 3, randomised, controlled trial.
    Yong K; Martin T; Dimopoulos MA; Mikhael J; Capra M; Facon T; Hajek R; Špička I; Baker R; Kim K; Martinez G; Min CK; Pour L; Leleu X; Oriol A; Koh Y; Suzuki K; Casca F; Macé S; Risse ML; Moreau P
    Lancet Haematol; 2024 Oct; 11(10):e741-e750. PubMed ID: 39067465
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A phase 1b study of once-weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma.
    Alsina M; Landgren O; Raje N; Niesvizky R; Bensinger WI; Berdeja JG; Kovacsovics T; Vesole DH; Fang B; Kimball AS; Siegel DS
    Am J Hematol; 2021 Feb; 96(2):226-233. PubMed ID: 33125764
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.